SBIR/STTR Research Award
SBIR Phase I: Development of a safe gene editing system via CRISPR-Cas and Cas inhibitor co-delivery
Award amount
$225,000Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- Acrigen Biosciences, Inc.
- Proposal award date
- 2020-08-15
- Contract end date
- 2021-01-31
- UEI
- GVHYYXAME436
- Solicitation number
- Not reported
- Topic code
- BM
Research abstract
The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to enable safe and effective human gene editing, providing therapies targeting myriad human genetic diseases. CRISPR (clustered, regularly interspaced, short palindrom
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR Phase II:Development of a safe gene editing system via CRISPR-Cas and Cas inhibitor co-delivery
- Enhancing CRISPR-mediated homology-directed repair using anti-CRISPR proteins
- Development of Safe in Utero Gene Editing Technology in Mice
- Discovery and applications of CRISPR-Cas inhibitor proteins
Research funding history
5 SBIR/STTR records share this UEI (2020–2022). Reported award amounts total $1,990,291. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, National Science Foundation